Raymond P Goodrich

List of Publications by Year
in descending order

114	4,775	94269 37	110170 64
papers	citations	h-index	g-index

122	122	122	2115
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion, 2004, 44, 877-885.	0.8	304
2	Riboflavin and UV-Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level. Photochemistry and Photobiology, 2004, 80, 15.	1.3	203
3	Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. Transfusion Medicine and Hemotherapy, 2011, 38, 8-18.	0.7	183
4	The Mirasolâ„¢ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfusion and Apheresis Science, 2006, 35, 5-17.	0.5	180
5	Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time. Transfusion, 2013, 53, 137S-149S.	0.8	171
6	A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion, 2010, 50, 2362-2375.	0.8	148
7	Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion, 2005, 45, 1335-1341.	0.8	147
8	Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation. Transfusion Medicine Reviews, 2008, 22, 133-153.	0.9	126
9	Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet, The, 2016, 387, 1753-1761.	6.3	114
10	Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion, 2005, 45, 911-919.	0.8	108
11	Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sanguinis, 2006, 90, 279-285.	0.7	108
12	Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sanguinis, 2006, 90, 85-91.	0.7	97
13	Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS ONE, 2020, 15, e0233947.	1.1	94
14	White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion, 2010, 50, 2489-2498.	0.8	85
15	Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sanguinis, 2004, 87, 82-90.	0.7	78
16	A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion, 2009, 49, 1205-1216.	0.8	77
17	Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals, 2010, 38, 20-30.	0.5	75
18	Functional inactivation of white blood cells by Mirasol treatment. Transfusion, 2006, 46, 642-648.	0.8	74

#	Article	IF	Citations
19	Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion and Apheresis Science, 2007, 37, 131-137.	0.5	74
20	Preservation of metabolic activity in lyophilized human erythrocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 967-971.	3.3	72
21	Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusionâ€associated graftâ€versusâ€host disease?. Transfusion, 2013, 53, 373-381.	0.8	72
22	Chemical and Biological Mechanisms of Pathogen Reduction Technologies. Photochemistry and Photobiology, 2014, 90, 957-964.	1.3	71
23	Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood, 2018, 132, 223-231.	0.6	71
24	Treatment With Riboflavin and Ultraviolet Light Prevents Alloimmunization to Platelet Transfusions and Cardiac Transplants. Transplantation, 2007, 84, 1174-1182.	0.5	63
25	Evaluation of the Mirasol platelet reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion, 2010, 50, 1019-1027.	0.8	52
26	Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2?/??c?/?double knockout mice. Transfusion, 2006, 46, 1553-1560.	0.8	51
27	Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion, 2013, 53, 284-290.	0.8	50
28	Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion, 2005, 45, 920-926.	0.8	47
29	In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet lightâ€“treated whole blood. Transfusion, 2011, 51, 1460-1468.	0.8	47
30	Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion, 2011, 51, 344-356.	0.8	46
31	The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sanguinis, 2011, 101, 208-214.	0.7	45
32	Establishment of the first International Repository for Transfusionâ€Relevant Bacteria Reference Strains: ISBT Working Party Transfusionâ€Transmitted Infectious Diseases (WPâ€TID), Subgroup on Bacteria. Vox Sanguinis, 2012, 102, 22-31.	0.7	44
33	In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion, 2010, 50, 2210-2219.	0.8	43
34	Riboflavin and ultraviolet light treatment of platelets triggers <scp>p</scp>38<scp>MAPK</scp> signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion, 2013, 53, 3164-3173.	0.8	43
35	Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion, 2011, 51, 808-815.	0.8	41
36	Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion, 2012, 52, 409-416.	0.8	40

#	Article	IF	Citations
37	Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion, 2007, 47, 240-247.	0.8	39
38	Fresh Whole Blood Use for Hemorrhagic Shock. Anesthesia and Analgesia, 2012, 115, 751-758.	1.1	39
39	Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates <scp>E</scp>bola virus in vitro. Transfusion, 2016, 56, S6-15.	0.8	39
40	Pathogen reduction technology (Mirasol^{Â®}) treated singleâ€donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sanguinis, 2009, 97, 234-239.	0.7	38
41	Inactivation of viruses in platelet and plasma products using a riboflavinâ€andâ€UVâ€"based photochemical treatment. Transfusion, 2015, 55, 1736-1744.	0.8	38
42	Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology. Blood Transfusion, 2017, 15, 357-364.	0.3	38
43	Defining â€œadequateâ€•pathogen reduction performance for transfused blood components. Transfusion, 2010, 50, 1827-1837.	0.8	37
44	IMMUNOHEMATOLOGY: Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion, 2009, 49, 2686-2699.	0.8	36
45	Pathogen reduction of whole blood: utility and feasibility. Transfusion Medicine, 2017, 27, 320-326.	0.5	36
46	Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion, 2013, 53, 860-867.	0.8	35
47	Development of a riboflavin and ultraviolet lightâ€based device to treat whole blood. Transfusion, 2013, 53, 131S-136S.	0.8	35
48	Selective inactivation of viruses in the presence of human platelets: UV sensitization with psoralen derivatives.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5552-5556.	3.3	34
49	Separation, Identification and Quantification of Riboflavin and its Photoproducts in Blood Products using High-performance Liquid Chromatography with Fluorescence Detection: A Method to Support Pathogen Reduction TechnologyÂ¶. Photochemistry and Photobiology, 2004, 80, 609.	1.3	34
50	Immune modulation and lack of alloimmunization following transfusion with pathogenâ€reduced platelets in mice. Transfusion, 2013, 53, 2697-2709.	0.8	33
51	Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method. Transfusion, 2015, 55, 815-823.	0.8	33
52	Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage. Transfusion, 2017, 57, 1218-1225.	0.8	32
53	Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at Ã¢Â^Â'30Ã‚Â°C. Vox Sanguinis, 2010, 98, 108-115.	0.7	31
54	Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion, 2005, 45, 1750-1758.	0.8	30

#	Article	IF	Citations
55	Treatment of Whole Blood With Riboflavin and UV Light. Shock, 2015, 44, 33-38.	1.0	30
56	Riboflavin and ultraviolet light: impact on dengue virus infectivity. Vox Sanguinis, 2016, 111, 235-241.	0.7	29
57	Inactivation of <scp>P</scp>lasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion, 2013, 53, 2278-2286.	0.8	28
58	Reduction ofLeishmania donovaniinfectivity in whole blood using riboflavin and ultraviolet light. Transfusion, 2015, 55, 326-329.	0.8	27
59	Refrigerated storage of lyophilized and rehydrated, lyophilized human red cells. Transfusion, 1993, 33, 322-329.	0.8	26
60	In vitro quality of singleâ€donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion, 2012, 52, 983-994.	0.8	26
61	Development of a mitochondrial <scp>DNA</scp> realâ€time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light. Vox Sanguinis, 2014, 107, 351-359.	0.7	25
62	DRAMATIC IMPROVEMENTS IN VIRAL INACTIVATION WITH BROMINATED PSORALENS, NAPHTHALENES AND ANTHRACENES. Photochemistry and Photobiology, 1993, 58, 59-65.	1.3	24
63	EPR spectroscopy of triplet aryl nitrenes covalently bound to .alpha.-chymotrypsin. Application of low-temperature methods to photoaffinity labeling. Journal of the American Chemical Society, 1988, 110, 6536-6541.	6.6	23
64	Preparation of cryoprecipitate from riboflavin and UV light-treated plasma. Transfusion and Apheresis Science, 2012, 46, 153-158.	0.5	23
65	An Action Spectrum of the Riboflavin-photosensitized Inactivation of Lambda PhageÂ¶. Photochemistry and Photobiology, 2005, 81, 474.	1.3	22
66	Reduced alloimmunization in mice following repeated transfusion with pathogenâ€reduced platelets. Transfusion, 2016, 56, 1419-1429.	0.8	22
67	Reduction of prion infectivity in packed red blood cells. Biochemical and Biophysical Research Communications, 2008, 377, 373-378.	1.0	21
68	BLOOD COMPONENTS: Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet lightâ€“treated platelet concentrates. Transfusion, 2009, 49, 2631-2636.	0.8	21
69	The effect of riboflavin and ultraviolet light on the infectivity of arboviruses. Transfusion, 2015, 55, 824-831.	0.8	21
70	Photochemical eradication of methicillinâ€resistant Staphylococcus aureus by blue light activation of riboflavin. Acta Ophthalmologica, 2017, 95, 498-502.	0.6	20
71	A pilot study to assess the hemostatic function of pathogenâ€reduced platelets in patients with thrombocytopenia. Transfusion, 2013, 53, 2043-2052.	0.8	18
72	Reduced <scp>MHC</scp> alloimmunization and partial tolerance protection with pathogen reduction of whole blood. Transfusion, 2017, 57, 337-348.	0.8	18

#	Article	IF	Citations
73	The design and development of selective, photoactivated drugs for sterilization of blood products. Drugs of the Future, 1997, 22, 159.	0.0	18
74	Evaluation of potential immune response and in vivo survival of riboflavinâ€ultraviolet lightâ€“treated red blood cells in baboons. Transfusion, 2009, 49, 64-74.	0.8	16
75	Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment. Proteomics - Clinical Applications, 2016, 10, 839-850.	0.8	16
76	A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model. Vaccines, 2021, 9, 340.	2.1	16
77	Efficiency of riboflavin and ultraviolet light treatment against high levels of biofilmâ€derived Staphylococcus epidermidis in buffy coat platelet concentrates. Vox Sanguinis, 2017, 112, 408-416.	0.7	14
78	Special considerations for the use of pathogen reduced blood components in pediatric patients: An overview. Transfusion and Apheresis Science, 2018, 57, 374-377.	0.5	14
79	Riboflavin and UVâ€Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level. Photochemistry and Photobiology, 2004, 80, 15-21.	1.3	13
80	Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment â€“ A comparative study. Transfusion and Apheresis Science, 2013, 49, 434-439.	0.5	12
81	The utility of pathogen inactivation technology: a real-life example of Leishmania infantum inactivation in platelets from a donor with an asymptomatic infection. Blood Transfusion, 2012, 10, 536-41.	0.3	12
82	Photochemical and Photophysical Studies of 3â€Aminoâ€6â€Iodoacridine and the Inactivation of Î» Phage. Photochemistry and Photobiology, 1996, 64, 622-631.	1.3	11
83	Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2years at â^'30Â°C. Transfusion and Apheresis Science, 2011, 44, 25-31.	0.5	11
84	Preservation of neutralizing antibody function in COVIDâ€19 convalescent plasma treated using a riboflavin and ultraviolet lightâ€based pathogen reduction technology. Vox Sanguinis, 2021, 116, 1076-1083.	0.7	11
85	Separation, Identification and Quantification of Riboflavin and its Photoproducts in Blood Products using HPLC with Fluorescence Detection: A Method to Support Pathogen Reduction Technology. Photochemistry and Photobiology, 2004, 80, 609-15.	1.3	11
86	Evaluation of Different Preparation Procedures of Pathogen Reduction Technology(Mirasol®)-Treated Platelets Collected by Plateletpheresis. Transfusion Medicine and Hemotherapy, 2009, 36, 309-315.	0.7	10
87	Generation of neutrophil priming activity by cellâ€containing blood components treated with pathogen reduction technology and stored in platelet additive solutions. Transfusion, 2011, 51, 1220-1227.	0.8	10
88	Characterization of posttransfusionPlasmodium falciparuminfection in semiâ€immune nonparasitemic patients. Transfusion, 2016, 56, 2374-2383.	0.8	10
89	Riboflavinâ€ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion, 2016, 56, 863-872.	0.8	10
90	Large animal evaluation of riboflavin and ultraviolet lightâ€“treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model. Transfusion, 2015, 55, 532-543.	0.8	9

#	Article	IF	Citations
91	Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes. Transfusion and Apheresis Science, 2018, 57, 683-688.	0.5	9
92	Survival of lyophilized and reconstituted human red blood cells in vivo. Transfusion Clinique Et Biologique, 1995, 2, 427-432.	0.2	8
93	An Action Spectrum of the Riboflavin Photosensitized Inactivation of Lambda Phage. Photochemistry and Photobiology, 2004, 81, 474-80.	1.3	8
94	Chapter 5. The Antiviral and Antibacterial Properties of Riboflavin and Light: Applications To Blood Safety and Transfusion Medicine. Comprehensive Series in Photochemical and Photobiological Sciences, 0, , 83-113.	0.3	7
95	The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial. Trials, 2022, 23, 257.	0.7	7
96	Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination. Journal of Visualized Experiments, 2015, , e52820.	0.2	6
97	Red Blood Cells Derived from Whole Blood Treated with Riboflavin and UV Light Maintain Adequate Cell Quality through 21 Days of Storage. Transfusion Medicine and Hemotherapy, 2019, 46, 240-247.	0.7	6
98	Improving blood safety and patient outcomes with pathogen reduction technology. Transfusion and Apheresis Science, 2011, 45, 229-238.	0.5	5
99	Quality of proteins in riboflavin and UV light-treated FFP during 1year of storage at â˜'18Â°C. Transfusion and Apheresis Science, 2012, 46, 15-18.	0.5	5
100	A novel cancer immunotherapy utilizing autologous tumour tissue. Vox Sanguinis, 2020, 115, 525-535.	0.7	5
101	Comparison of computerized formulae for determination of platelet recovery and survival. Transfusion, 2005, 45, 1237-1239.	0.8	4
102	Pilot Acute Safety Evaluation of Innocellâ„¢ Cancer Immunotherapy in Canine Subjects. Journal of Immunology Research, 2020, 2020, 1-8.	0.9	4
103	Ignorance is not bliss. Transfusion, 2018, 58, 615-616.	0.8	3
104	Improved in vitro quality of stored red blood cells upon oxygen reduction prior to riboflavin/UV light treatment of whole blood. Transfusion, 2019, 59, 3197-3204.	0.8	3
105	Separation, Identification and Quantification of Riboflavin and its Photoproducts in Blood Products using Highâ€performance Liquid Chromatography with Fluorescence Detection: A Method to Support Pathogen Reduction Technology^{Â¶}. Photochemistry and Photobiology, 2004, 80, 609-615.	1.3	2
106	An Action Spectrum of the Riboflavinâ€photosensitized Inactivation of Lambda Phage^{Â¶}. Photochemistry and Photobiology, 2005, 81, 474-480.	1.3	2
107	Releasates of riboflavin/ UV â€treated platelets: Microvesicles suppress cytokineâ€mediated endothelial cell migration/proliferation. Transfusion, 2021, 61, 1551-1561.	0.8	2
108	Spectroscopy Of Nitrenes Bound To â^•Chymotrypsin. Proceedings of SPIE, 1988, 0847, 57.	0.8	1

#	Article	IF	Citations
109	In Reply to: â€œIs the SCID mouse model applicable to human acute lung injury?â€• Transfusion, 2012, 52, 2489-2492.	0.8	1
110	Measurement of Transmitted Light as an Indicator of Cryopreserved Platelet Viability. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 107-116.	0.5	0
111	In response to Morrisonâ€McKell and wehrli. Journal of Clinical Apheresis, 2012, 27, 346-347.	0.7	0
112	Pathogen Reduction Technologies. , 2013, , 295-300.		0
113	Vitamin B2 and Innovations in Improving Blood Safety. , 0, , .		0
114	Commentary for <scp>ISBT</scp> Seriesâ€”â€˜All For One and One For Allâ€™. ISBT Science Series, 2019, 14, 257-259.	1.1	0